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MLL gene aberrations are frequently diagnosed in infant acute myeloid leukemia (AML). We previously
described the MLL-NEBL and NEBL-MLL genomic fusions in an infant AML patient with a chromosomal
translocation t(10;11)(p12;q23). NEBL was the second Nebulin family member (LASP1, NEBL) which
was found to be involved in MLL rearrangements. Here, we report on our attempts to unravel the onco-
genic properties of both fusion genes. First, RT-PCR analyses revealed the presence of the MLL-NEBL and
NEBL-MLL mRNAs in the diagnostic sample of the patient. Next, expression cassettes for MLL-NEBL and
NEBL-MLL were cloned into a sleeping beauty vector backbone. After stable transfection, the biological
effects of MLL-NEBL, NEBL-MLL or the combination of both fusion proteins were investigated in a condi-
tional cell culture model. NEBL-MLL but also co-transfected cells displayed signiﬁcantly higher growth
rates according to the data obtained by cell proliferation assay. The focus formation experiments revealed
differences in the shape and number of colonies when comparing MLL-NEBL, NEBL-MLL- and co-transfec-
ted cells. The results obtained in this study suggest that the reciprocal fusion genes of the Nebulin gene
family might be of biological importance.
 2013 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
MLL gene rearrangements constitute the most frequently iden-
tiﬁed genetic aberration correlated with the development of acute
lymphoblastic (ALL) or acute myeloid leukemia (AML) in early in-
fancy (612 months of age). The MLL recombinome comprises to
date more than 70 direct translocation partner genes (dTPGs) that
have been identiﬁed and described at the molecular level [1]. In
addition, about 50 reciprocal MLL fusion alleles, fusing a large
number of different genes reciprocally to the 30-portion of the
MLL gene (rTPGs) have been described as well [1]; they derive
mostly from complex rearrangements involving the MLL gene in
conjunction with the main fusion partner genes AFF1, MLLT3,
MLLT4, MLLT10, MLLT1, MLLT11 and SEPT6. However, in single pa-
tient cases, in-frame reciprocal fusion of 50-gene portions
(RNF115, RABGAP1L, LASP1, MAML2, MEF2C, NKAIN2, CDK6, APBB1IP,
ADARB2, ATG16L2, UVRAG, MYO18A and GPSN2) with the 30-gene
portion of the MLL gene were identiﬁed. The biological properties
of these reciprocal fusion proteins have yet not been investigated.Despite our molecular knowledge about the oncogenic func-
tions of a few direct MLL fusions proteins (MLL-AFF1, MLL-MLLT1,
MLL-MLLT3, MLL-MLLT4, MLL-MLLT10, and MLL-ELL) [2–7]; and
one reciprocal MLL fusion protein (AFF1-MLL) [8], relatively little
is known about the pathological disease mechanisms that are
caused by the majority of known MLL fusion proteins. Most likely
are the ectopic transcription of HOXA genes in conjunction with
MEIS1 in case of AML patients, and/or ectopic H3K79me2/3 chroma-
tin methylation patterns caused by arbitrary functions of several
MLL fusions proteins when binding to the AFF1 or AFF4 super elon-
gation complex (for review see [9]). The large heterogeneity ofMLL
fusion partners (membrane, cytosolic and nuclear proteins) makes
it nearly impossible to deﬁne a minimal property that would
explain disease development by a common mechanism. Therefore,
each fusion has to be investigated by its own without any prior
assumptions. For this purpose, we started to investigate the direct
and reciprocal MLL fusion protein from a recently discovered novel
MLL translocation.
In 2010, we described Nebulette (NEBL) as a novel MLL-TPG in
an infant case of AML bearing a chromosomal translocation
t(10;11)(p12;q23) [10]. Brieﬂy, an 11-month-old boy was referred
to the hospital with clinical suspicion of acute leukemia and labo-
ratory tests were consistent with AML-M5 subtype; the infant died
1 month after diagnosis. The NEBL protein, also known as LASP2,
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found in the cytoplasm and plays a critical role in the dynamic
organization of the cytoskeleton [11,12]. The Nebulin family is
comprised by three muscle speciﬁc proteins (NEBULIN, NEBU-
LETTE, and N-RAP) and two small non-muscle proteins (LIM-Neb-
ulette and LASP1). Furthermore, NEBL/LASP2 has been recently
described as dynamic focal adhesion protein that associates with
a-catenin, thereby regulating the rate of attachment and spreading
of ﬁbroblasts on ﬁbronectin coated dishes when ectopically ex-
pressed [13].
Interestingly, the LASP1 gene has been earlier described as an
MLL-TPG in an infant AML patient [14]. Therefore, NEBL represents
only the second Nebulin protein family member which was found
to be recombined with the MLL gene in AML patients. The NEBL
gene codes for a sarcomeric and a non-muscle isoform (Fig. 1A).
The sarcomeric isoform (28 exons, 107 kDa) is exclusively ex-
pressed in cardiac muscle while the non-muscle isoform (7 exons,
31.2 kDa) is expressed in non-muscle tissues, similarly to what is
known about the LASP1 gene. Not unexpected, the chromosomal
breakpoint was identiﬁed in the coding region of the non-muscle
isoform. In particular, the reciprocal recombination event took
place in NEBL intron 3 and in MLL intron 9.
The potential oncogenic effect of the homologous MLL-LASP1
fusion protein has already been tested by retroviral transduction
experiments. This fusion gene was expressed in murine bone
marrow (BM) cells, however, transduced cells failed to form colo-
nies in replating experiment performed with methylcellulose
[14]. Hence, the authors described LASP1 as an MLL TPG with a
cytoplasmic localization that has no in vitro transformation capa-
bility. Since we identiﬁed the second member of the same protein
family, we wanted to test potential oncogenic effects in an unbi-
ased fashion. Based on the previous ﬁndings with MLL-LASP1, we
assumed that the MLL-NEBL fusion protein may also fail to display
oncogenic properties. Therefore, we included also the reciprocal
NEBL-MLL fusion allele and the combination of both alleles in our
experiments.Fig. 1. (A) The genetic fusion of MLL and NEBL in an AML patient occurred within the non
region of MLL (intron 9). The gene structures are indicated and the recombination site is
transcripts. (C) CCK-8 assay for control cells, mock-transfected cells (vector backbones T
(MN and NM).2. Materials and methods
2.1. Patient sample
Total RNA was isolated from mononuclear BM cells of the patient using the TRI-
zol reagent kit (Invitrogen, Carlsbad, CA, USA) according to the instruction of the
manufacturer, and 2 lg were reverse transcribed using Superscript reverse trans-
criptase (Invitrogen, Carlsbad, CA, USA). The integrity of cDNA was always exam-
ined by amplifying a fragment of the GAPDH gene (519 bp). Informed consent
was obtained from the patients’ parents.
2.2. Cloning of cDNA expression constructs
The sleeping beauty vector design (Tet-on) displayed in Fig. 2A was used to ex-
press the MLL-NEBL and NEBL-MLL fusion proteins. Due to our cloning strategy,
coding sequences for MLL and NEBL, or vice versa, for NEBL and MLL were separated
by a small intron of 218 and 245 bp, respectively. The resulting expression cassettes
forMLL-NEBL (exons 1–9::4–7) and NEBL-MLL (exons 1–3::14–37) were then cloned
into two different sleeping beauty vector backbones (TCGP: Teton::MLL-(218 bp in-
tron)-NEBL//PGK::GFP-rtTA-PuroR; TCRP: Teton::NEBL-(245 bp intron)-MLL//
PGK::RFP-rtTA-PuroR) which allow the inducible expression of both MLL fusion pro-
teins together with either a green or red ﬂuorescent protein, the rtTA Protein and
the Puromycin resistance gene.
2.3. Stable transfection of HEK293T and mouse embryonic ﬁbroblast (MEF) cells
All vectors were transfected together with sleeping beauty transposase expres-
sion vector (SB100X) and stable cell clones (green or red) were selected for 7 days
in Puromycin-containing medium. This was enough to obtain stable cell lines with
about 1–5 integrated vectors per cell in the genomic DNA. This was validated
with the following oligonucleotides: MLL-NEBL vector copies were quantiﬁed with
MLL.E9.F (5-gcctcagccacctactacag-3) and NEBL.E4.NR (5-caggagtgtccgtgacgatgct
gaag-3); NEBL-MLL vector copies were quantiﬁed with MLL.E14.R (5-atgacacag
tgagaaatcatgagac-3) and NEBL.RC.E3F (5-ggcagatacacctgaaaatcttcgcctga-3). Copy
numbers were quantiﬁed against an unrelated single copy tRNA gene locus localized
on chromosome19: Chr19.tRNA.F (5-ccccttactttgggatgagtccaca-3) andChr19.tRNA.R
(5-catgcggaaaccggaacctg). The sizes of the amplimers was 454, 396 and 622 bp,
respectively (see Supplementary Fig. S1A). Cell cultures displayed a homogenous
population with about 99–100% ﬂuorescent cells after 7 days. After 4 weeks without
Puromycin selection, cells were reevaluated by ﬂuorescence microscopy to reassure
the stable integration of transgenes. After this period the stable cell lines, either
HEK293T (cell growth assay) or MEF (focus formation assay), were molecularly ana-
lyzed for proper plasmid integration and doxycycline-dependent transcription of-muscle form of the NEBL gene (intron 3) and within the known breakpoint cluster
indicated by a dashed line. (B) RT-PCR analyses of MLL-NEBL and NEBL-MLL fusion
CGP and TCRP) as well as MLL-NEBL (MN), NEBL-MLL (NM) and co-transfected cells
Fig. 2. Focus formation experiment. (A) Experimental outline: The inducible RAS expression system (Tet-off) was used as described in Gausmann et al. [16]. The displayed
sleeping beauty vector design (Tet-on) was used to express the MLL-NEBL and NEBL-MLL fusion proteins. ITR: inverted terminal repeats. TRE: Tetracyclin-response element
promoter. pA: poly-adenylation site. GFP/RFP: green/red ﬂuorescent protein. 2A: cleavage site. rtTA: reverse Tet-repressor. Puro: Puromycin resistance. Mcs: multiple cloning
site for cloning either MLL-NEBL or NEBL-MLL coding sequence. (B) Focus formation assay. Left: bright ﬁeld pictures of non-induced and induced cells. Middle: ﬂuorescent
pictures demonstrating for the expression of MLL-NEBL (green) and NEBL-MLL (red). Right: photographs taken from the stained 60 mm petri dishes.
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tween the coding sequences for MLL-NEBL and NEBL-MLL, transcription and correct
splicing was validated by RT-PCR experiments after 5 days of doxycycline induction
(1 lg/ml; see Supplementary Fig. S1B). For this purpose, RNA was isolated using the
RNeasy Kit (Qiagen, Hilden, Germany) and the RNase free DNase Kit (Qiagen). One
microgram RNA was reverse transcribed into cDNA using Superscript reverse trans-
criptase (Invitrogen, Karlsruhe, Germany) following themanufacturer’s instructions.
RT-PCR analysis was performed again with the above mentioned oligonucleotides
(MLL-NEBL: MLL.E9.F  NEBL.E4.NR; NEBL-MLL: MLL.E14.R  NEBL.RC.E3F), which
bind to complementary exonic sequences of both fusion genes, as depicted in Supple-
mentary Fig. S1C. Oligonucleotides used for RT-PCR analyses of patientmaterial were
for MLL-NEBL: lane 1: MLL F1A (5-CCACCTACTACAGGACCGCCAAGAAAA-
3)  NEBL.E4.R (5-GTAGCTCAGGAGTGTCCGTGACGATGC-3); lane 2: MLL
F1A  NEBL.E4.NR (5-CAGGAGTGTCCGTGACGATGCTGAAG-3); lane 3: MLL F2
(5-GTGGCTCCCCGCCCAAGTATCCCTGTAAAAC-3)  NEBL.E4.NR; lane 4: MLLF2A3
(5-AGGTCCAGAGCAGAGCAAACAGAAAAA-3)  NEBL.E4.NR; similarly, NEBL-MLL
transcripts in the patient cDNA was analyzed accordingly: lanes 1 and 2: NE-
BL003.E2F (5-CTGCAAGATGGCACTCAACATGAACAACTA-3) MLLR3 (5-CTACTGG-
CACAGAGAAAGCAAACCACCCTGG-3), lanes 3 and 4: NEBL3.3 (5-CACGGTGG
CAGATACACC-3) MLLR3. All resulting PCR amplimers were cut out from the gel
and subjected to sequence analyses (data not shown).
2.4. Cell Counting Kit-8 (CCK-8) assay
The commercially available CCK-8 assay (Dojindo Molecular Technologies Inc.,
Rockville, MD, USA) has been used to measure cell growth. After obtaining stably
transfected HEK293T cells with the above mentioned vector constructs (see
Fig. 2), cells were grown in the presence of doxycycline for 5 days under normal cell
culture conditions (Dulbecco’s modiﬁed Eagle’s medium (DMEM)/10% fetal calf ser-
um (FCS)/1% Gln/1% Pen-Strep). The absorption was measured at 450 nm using an
ELISA reader (Pegasus Scientiﬁc, MD, USA). CCK-8 assays were performed 3 times in
triplicates over 96 h.2.5. Focus formation experiments
Control and stably transfected MEF cells were treated with or without 1 lg/ml
doxycycline to generate independent cultures with fusion protein expression
turned on or off. Cells were seeded in 60 mm petri dishes (1  104 cells) and cell
growth was daily monitored over a period of 14 days. After this time period, all cells
were ﬁxed with formalin and stained with 1 mg/mL methylene blue solution. Re-
sults are exemplary shown of a single experiment. All experiments have been per-
formed in triplicates.3. Results
We ﬁrst conﬁrmed by RT-PCR that both genomic fusion alleles
gave rise to the expected fusion transcripts. For this purpose we
designed a series of primers to identify the proper fusions of
MLL-NEBL and NEBL-MLL mRNAs in the total RNA isolated from
diagnostic BM samples of the AML patient (Fig. 1B). Since the NEBL
gene can be expressed as muscle-speciﬁc and as non-muscle tran-
script by completely different exons, we ﬁnally identiﬁed by se-
quence analysis of obtained PCR amplimers that exon 9 of MLL
was fused in-frame with exon 4 of NEBL, while exon 3 of NEBL
was fused in-framewith exon 11 of theMLL gene. Due to our cloning
strategy, we separated the coding sequences for MLL and NEBL, or
vice versa, for NEBL and MLL by small introns. The resulting expres-
sion cassettes for MLL-NEBL (exons 1–9::4–7) and NEBL-MLL (exons
1–3::14–37) were then cloned into two different sleeping beauty
vector backbones TCGP and TCRP (TCGP: Teton::MLL-(218 bp
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intron)-MLL//PGK::RFP-rtTA-PuroR). Both vectors allow the induc-
ible transcription of both reciprocal MLL fusion genes with either
a green or red ﬂuorescent protein, the rtTA Protein and the Puro-
mycin resistance gene. After transfection and selection of stable
cell lines, we ﬁrst validated by RT-PCR that the introns located be-
tween MLL and NEBL, or vice versa, are correctly spliced out.
Next, we investigated the growth properties of stable cells that
express either MLL-NEBL, NEBL-MLL or both fusion proteins. The
results obtained in these experiments demonstrate that NEBL-
MLL-transfected cells displayed a signiﬁcantly higher growth rate,
compared to the other cultures and appropriate controls
(Fig. 1C). We repeated this experiment several times but the results
were always the same: cells expressing the NEBL-MLL fusion pro-
tein displayed the highest growth advantage. Even co-transfected
cells were growing faster than MLL-NEBL expressing cells or
mock-transfected cells.
Finally, focus formation experiments were performed (see
Fig. 2A). For the purpose of this experiment, cells were seeded in
small petri dishes (1  104 cells) and transgene expression was
either induced or non-induced. All non-induced cultures (mock
control, positive HRAS⁄ control, MLL-NEBL, NEBL-MLL, or both fu-
sion genes) behaved similar and normal cell growth stopped after
reaching conﬂuency, as summarized in Fig. 2B. By contrast, when
transgene expression was turned on, NEBL-MLL and co-transfected
cells showed typical signs of growth transformation, comparable to
those observed for the positive HRAS⁄ control. Fig. 2B displays only
pictures of a single experiment, while all experiments were per-
formed in triplicates and independently repeated at least for three
times. Based on these data, NEBL-MLL fusion protein alone or in
conjunction with MLL-NEBL displayed a ‘‘loss-of-contact inhibi-
tion’’ with small round colonies. This type of loss-of-contact inhibi-
tion in conjunction with the capacity to form rounded colonies
most likely represents an oncogenic feature. By contrast, cells
expressing only the MLL-NEBL fusion protein displayed only a
slight loss-of-contact inhibition phenotype and no such colony
shapes. In all experiments that we repeated for several times,
MLL-NEBL scored always less than NEBL-MLL expressing cells or
the stably co-transfected cells.4. Discussion
Based on the fusion RNAs of a single AML patient that was diag-
nosed with a reciprocal chromosomal translocation involving MLL
and NEBL [10], we successfully reconstructed both fusion genes.
The RT-PCR data suggest that the MLL-NEBL fusion protein exhibits
the N-terminal portion of MLL fused to a serine-rich linker region
and the SH3 domain of NEBL, similar to the investigated MLL-
LASP1 fusion protein. The reciprocal NEBL-MLL fusion gene en-
codes a protein, where the N-terminal LIM domain is fused to
the C-terminal portion of the MLL protein. Both fusion alleles were
cloned into a sleeping beauty vector backbone (see Fig. 2A) that al-
lowed not only an inducible expression of both transgenes in a
doxycycline-dependent fashion, but also the constitutive expres-
sion of either the green or red ﬂuorescent protein. Thus, all our
experiments could be easily controlled by the ﬂuorescence of the
fusion gene expressing cells.
Doxycycline-dependent expression of MLL-NEBL, NEBL-MLL
and of both fusion protein together was used to analyze the growth
properties and to test for oncogenic functions. Cell growth was
signiﬁcantly enhanced in the presence of NEBL-MLL, while co-
transfected cells and MLL-NEBL cells displayed a less-accelerated
growth phenotype. A similar observation was obtained in the per-
formed focus formation assays. In case of MLL-NEBL, we do see
some foci, however the shape of these foci was different comparedto the shapes observed for NEBL-MLL or the co-transfected cells.
NEBL-MLL or co-transfected cells always displayed a much larger
number of round-shaped foci, as displayed in Fig. 2B. This is quite
similar to the observations obtained with retrovirally transduced
MLL-LASP1 that was unable to form colonies in methylcellulose
[14].
The conclusion drawn from these experiments is that either the
reciprocal NEBL-MLL fusion protein alone – or the combination of
both reciprocal fusion proteins – confer a strong growth promoting
activity and always displayed a loss-of-contact inhibition pheno-
type. The observed phenotype of the foci was very similar to what
we observed in the control experiments which we performed with
the HRAS⁄ oncoprotein. Since NEBL and LASP1 represent proteins
of the same protein family, we performed next focus formation
experiments with the homologous MLL-LASP1 and LASP1-MLL fu-
sion protein. We observed a rapid focus formation activity (after
5 days) in stably transfected and doxycycline-treated cells only
with LASP1-MLL (see Supplementary Fig. S1D), while MLL-LASP1
expressing cells display a retarded focus formation phenotype,
with only few foci after 14 days. All this illustrates the complexity
ofMLL-rearranged leukemia, and moroever, underscores to the no-
tion that the reciprocalMLL fusion alleles may be of importance for
oncogenic transformation.
This is quite similar to what has recently been demonstrated
in vitro and in vivo for the reciprocal AF4-MLL fusion allele
[8,15,16]. The AF4-MLL fusion protein was able to confer focus for-
mation in vitro, but was also capable of inducing a pro-B ALL dis-
ease phenotype in a murine transduction/transplantation model.
Our results might be a hint that reciprocal fusion alleles involving
Nebulin gene family members andMLL are of clinical importance. If
our data can be substantiated by mouse experiments, we have to
reevaluate our thinking about the role of dTPG and rTPG fusions
in MLL-mediated leukemia.Acknowledgements
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